Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. develops therapies for central nervous system, inflammatory and cardiometabolic diseases as a late-stage biopharmaceutical company. News about RVPH centers on brilaroxazine (RP5063), a clinical-stage program for schizophrenia and other neuropsychiatric indications, as well as RP1208, with both drug candidates described as new chemical entities discovered in-house.
Recurring updates include clinical and regulatory communications, intellectual-property strategy, peer-reviewed data publications, corporate presentations, annual and interim financial results, and equity or warrant financings used to support research and development and working capital.
Reviva (OTCQB: RVPH) announced that Founder, President and CEO Laxminarayan Bhat, PhD, will join a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on Wednesday, May 20, 2026, from 2:40–3:00 PM ET. Investors can register to watch the session online.
Reviva (RVPH) reported first quarter 2026 results and development progress for brilaroxazine. Net loss was about $3.2 million ($0.46/share), versus $6.4 million ($2.61/share) a year earlier. Cash and equivalents rose to $22.2 million from $14.4 million.
The company filed a U.S. composition of matter provisional patent for a new form of brilaroxazine potentially extending exclusivity to 2046, and expects FDA feedback on its use in the RECOVER-2 Phase 3 schizophrenia trial and future NDA in mid‑2026. Patient enrollment in RECOVER-2 is expected to start in Q3 2026.
Reviva completed a $10.0 million public equity offering in March 2026 and plans partnership discussions. Its common stock is set to transition from a Nasdaq listing to OTCQB on May 14, 2026, with ticker RVPH unchanged.
Reviva (NASDAQ: RVPH) announced that CEO Laxminarayan Bhat, PhD, will participate in an A.G.P. fireside chat on April 27, 2026 at 11:00 AM ET to discuss the clinical-stage drug candidate brilaroxazine and upcoming clinical, regulatory, and IP milestones.
A live webcast link is available for investors and interested parties to watch the discussion.
Reviva Pharmaceuticals (NASDAQ: RVPH) published a shareholder letter on April 15, 2026 outlining recent financing, clinical and IP actions to advance brilaroxazine. The company closed a $10 million financing and reported ~$23 million in cash, targeting funding into Q1 2027.
Key priorities: pursue FDA alignment on a new API/form to extend exclusivity (potentially through 2046), file a composition-of-matter patent, initiate RECOVER-2 Phase 3 activities in Q2 2026, and begin U.S. enrollment in Q3 2026 with expected study completion in Q4 2027.
Reviva (NASDAQ: RVPH) reported full-year 2025 results and business updates on March 30, 2026. The company disclosed a net loss of $19.9M for 2025 and cash of $14.4M at year-end. Reviva received FDA written recommendations calling for a second Phase 3 trial and plans to initiate RECOVER-2 in mid-2026. The company completed NDA-enabling studies, cGMP registration manufacturing, and raised gross proceeds from public offerings in 2025–2026.
Reviva Pharmaceuticals (NASDAQ: RVPH) closed a public offering on March 20, 2026, raising approximately $10.0 million gross by selling 6,666,667 common shares with accompanying Series G and Series H warrants at a combined price of $1.50 per share and warrant package.
The Series G and H warrants have a $1.50 exercise price; G warrants expire in five years and H warrants expire in 12 months. The company reported approximately $23 million cash post-close, which it believes funds operations into Q1 2027, and intends to use proceeds to fund R&D including the RECOVER-2 Phase 3 trial for brilaroxazine, plus working capital.
Reviva Pharmaceuticals (NASDAQ: RVPH) priced a public offering to raise approximately $10.0 million by selling 6,666,667 common shares with attached Series G and Series H warrants at a combined price of $1.50 per share and warrant.
The Series G and Series H warrants have an exercise price of $1.50; G warrants expire five years and H warrants expire 12 months from issuance. Closing is expected on or about March 20, 2026. The company intends to use proceeds to fund R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and general corporate purposes.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced on March 18, 2026 that it intends to conduct a public offering of its common stock (or equivalents) and warrants. The offering is subject to market conditions and may not be completed.
The company said it plans to use net proceeds and existing cash to fund research and development, including the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital. A.G.P./Alliance Global Partners is the sole placement agent. The securities will be offered under an effective Form S-3 shelf registration declared effective February 13, 2024.
Reviva (NASDAQ: RVPH) announced publication on Jan 8, 2026 in Biological Psychiatry reporting vocal biomarker findings from the RECOVER Phase 3 trial of brilaroxazine for schizophrenia. The paper presents speech latency as an interpretable vocal biomarker that classifies moderate-to-severe vs low negative symptoms, correlates with clinician-assessed efficacy, and identifies a subgroup (VBM-positive) with stronger, faster responses to brilaroxazine. The authors state speech latency can be measured from psychiatric interviews across languages and may be used to enrich trials, reduce sample-size needs, and lower trial costs and placebo effects.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will present a corporate presentation at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026 in San Francisco.
Presentation details: Date: January 11, 2026; Time: 1:20 PM PT; Presenter: Laxminarayan Bhat, Ph.D.; Location: Marines’ Memorial Club, San Francisco, CA.